Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis - PubMed (original) (raw)
. 2009 Mar;296(3):H893-9.
doi: 10.1152/ajpheart.01038.2008. Epub 2009 Jan 30.
Affiliations
- PMID: 19181962
- DOI: 10.1152/ajpheart.01038.2008
Free article
Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis
Jens Kroll et al. Am J Physiol Heart Circ Physiol. 2009 Mar.
Free article
Abstract
Vascular endothelial growth factor (VEGF) is an endothelial-specific growth factor that activates the small GTPase RhoA. While the role of RhoA for VEGF-driven endothelial migration and angiogenesis has been studied in detail, the function of its target proteins, the Rho-dependent kinases ROCK I and II, are controversially discussed. Using the mouse model of oxygen-induced proliferative retinopathy, ROCK I/II inhibition by H-1152 resulted in increased angiogenesis. This enhanced angiogenesis, however, was completely blocked by the VEGF-receptor antagonist PTK787/ZK222584. Loss-of-function experiments in endothelial cells revealed that inhibition of ROCK I/II using the pharmacological inhibitor H-1152 and ROCK I/II-specific small-interfering RNAs resulted in a rise of VEGF-driven sprouting angiogenesis. These functional data were biochemically substantiated by showing an enhanced VEGF-receptor kinase insert domain receptor phosphorylation and extracellular signal-regulated kinase 1/2 activation after inhibition of ROCK I/II. Thus our data identify that the inhibition of Rho-dependent kinases ROCK I/II activates angiogenesis both, in vitro and in vivo.
Comment in
- Role of ROCK I/II in vascular branching.
van Nieuw Amerongen GP, van Hinsbergh VW. van Nieuw Amerongen GP, et al. Am J Physiol Heart Circ Physiol. 2009 Apr;296(4):H903-5. doi: 10.1152/ajpheart.00125.2009. Epub 2009 Feb 13. Am J Physiol Heart Circ Physiol. 2009. PMID: 19218507 No abstract available.
Similar articles
- Fasudil-induced hypoxia-inducible factor-1alpha degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells.
Takata K, Morishige K, Takahashi T, Hashimoto K, Tsutsumi S, Yin L, Ohta T, Kawagoe J, Takahashi K, Kurachi H. Takata K, et al. Mol Cancer Ther. 2008 Jun;7(6):1551-61. doi: 10.1158/1535-7163.MCT-07-0428. Mol Cancer Ther. 2008. PMID: 18566226 - Antiangiogenic properties of fasudil, a potent Rho-Kinase inhibitor.
Hata Y, Miura M, Nakao S, Kawahara S, Kita T, Ishibashi T. Hata Y, et al. Jpn J Ophthalmol. 2008 Jan-Feb;52(1):16-23. doi: 10.1007/s10384-007-0487-5. Epub 2008 Mar 28. Jpn J Ophthalmol. 2008. PMID: 18369695 - Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo.
Yin L, Morishige K, Takahashi T, Hashimoto K, Ogata S, Tsutsumi S, Takata K, Ohta T, Kawagoe J, Takahashi K, Kurachi H. Yin L, et al. Mol Cancer Ther. 2007 May;6(5):1517-25. doi: 10.1158/1535-7163.MCT-06-0689. Mol Cancer Ther. 2007. PMID: 17513600 - Could pharmacological curtailment of the RhoA/Rho-kinase pathway reverse the endothelial barrier dysfunction associated with Ebola virus infection?
Eisa-Beygi S, Wen XY. Eisa-Beygi S, et al. Antiviral Res. 2015 Feb;114:53-6. doi: 10.1016/j.antiviral.2014.12.005. Epub 2014 Dec 13. Antiviral Res. 2015. PMID: 25512227 Review. - Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.
Shi J, Wei L. Shi J, et al. J Cardiovasc Pharmacol. 2013 Oct;62(4):341-54. doi: 10.1097/FJC.0b013e3182a3718f. J Cardiovasc Pharmacol. 2013. PMID: 23921309 Free PMC article. Review.
Cited by
- Mass spectrometry-based multi-omics analysis reveals distinct molecular features in early and advanced stages of hepatocellular carcinoma.
Fan M, Hu J, Xu X, Chen J, Zhang W, Zheng X, Pan J, Xu W, Feng S. Fan M, et al. Heliyon. 2024 Sep 20;10(19):e38182. doi: 10.1016/j.heliyon.2024.e38182. eCollection 2024 Oct 15. Heliyon. 2024. PMID: 39381095 Free PMC article. - Selective ROCK Inhibitor Enhances Blood Flow Recovery after Hindlimb Ischemia.
Fayed HS, Bakleh MZ, Ashraf JV, Howarth A, Ebner D, Al Haj Zen A. Fayed HS, et al. Int J Mol Sci. 2023 Sep 22;24(19):14410. doi: 10.3390/ijms241914410. Int J Mol Sci. 2023. PMID: 37833857 Free PMC article. - RhoA/ROCK Signaling Is Involved in Pathological Retinal Neovascularization.
Tang F, Huang K, Peng B, Deng W, Su N, Xu F, Zhang M, Zhong H. Tang F, et al. J Vasc Res. 2023;60(4):183-192. doi: 10.1159/000533321. Epub 2023 Sep 1. J Vasc Res. 2023. PMID: 37660689 Free PMC article. - Y-27632 Impairs Angiogenesis on Extra-Embryonic Vasculature in Post-Gastrulation Chick Embryos.
Duess JW, Gosemann JH, Kaskova Gheorghescu A, Puri P, Thompson J. Duess JW, et al. Toxics. 2023 Jan 30;11(2):134. doi: 10.3390/toxics11020134. Toxics. 2023. PMID: 36851009 Free PMC article. - Active RhoA Exerts an Inhibitory Effect on the Homeostasis and Angiogenic Capacity of Human Endothelial Cells.
Hauke M, Eckenstaler R, Ripperger A, Ender A, Braun H, Benndorf RA. Hauke M, et al. J Am Heart Assoc. 2022 Jun 21;11(12):e025119. doi: 10.1161/JAHA.121.025119. Epub 2022 Jun 14. J Am Heart Assoc. 2022. PMID: 35699166 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases